These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 16951229)

  • 1. Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome.
    Fischer M; Oberthuer A; Brors B; Kahlert Y; Skowron M; Voth H; Warnat P; Ernestus K; Hero B; Berthold F
    Clin Cancer Res; 2006 Sep; 12(17):5118-28. PubMed ID: 16951229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
    Warnat P; Oberthuer A; Fischer M; Westermann F; Eils R; Brors B
    BMC Cancer; 2007 May; 7():89. PubMed ID: 17531100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of DEIN, a novel gene with high expression levels in stage IVS neuroblastoma.
    Voth H; Oberthuer A; Simon T; Kahlert Y; Berthold F; Fischer M
    Mol Cancer Res; 2007 Dec; 5(12):1276-84. PubMed ID: 18171985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification.
    Oberthuer A; Berthold F; Warnat P; Hero B; Kahlert Y; Spitz R; Ernestus K; König R; Haas S; Eils R; Schwab M; Brors B; Westermann F; Fischer M
    J Clin Oncol; 2006 Nov; 24(31):5070-8. PubMed ID: 17075126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYCN protein expression as a predictor of neuroblastoma prognosis.
    Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
    Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
    Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
    Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q.
    McArdle L; McDermott M; Purcell R; Grehan D; O'Meara A; Breatnach F; Catchpoole D; Culhane AC; Jeffery I; Gallagher WM; Stallings RL
    Carcinogenesis; 2004 Sep; 25(9):1599-609. PubMed ID: 15090470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translating expression profiling into a clinically feasible test to predict neuroblastoma outcome.
    Schramm A; Vandesompele J; Schulte JH; Dreesmann S; Kaderali L; Brors B; Eils R; Speleman F; Eggert A
    Clin Cancer Res; 2007 Mar; 13(5):1459-65. PubMed ID: 17332289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status.
    Westermann F; Henrich KO; Wei JS; Lutz W; Fischer M; König R; Wiedemeyer R; Ehemann V; Brors B; Ernestus K; Leuschner I; Benner A; Khan J; Schwab M
    Clin Cancer Res; 2007 Aug; 13(16):4695-703. PubMed ID: 17652624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients.
    Henrich KO; Fischer M; Mertens D; Benner A; Wiedemeyer R; Brors B; Oberthuer A; Berthold F; Wei JS; Khan J; Schwab M; Westermann F
    Clin Cancer Res; 2006 Jan; 12(1):131-8. PubMed ID: 16397034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of gene expression-based classification for neuroblastoma.
    Oberthuer A; Hero B; Berthold F; Juraeva D; Faldum A; Kahlert Y; Asgharzadeh S; Seeger R; Scaruffi P; Tonini GP; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Vandesompele J; Vermeulen J; Speleman F; Noguera R; Piqueras M; Bénard J; Valent A; Avigad S; Yaniv I; Weber A; Christiansen H; Grundy RG; Schardt K; Schwab M; Eils R; Warnat P; Kaderali L; Simon T; Decarolis B; Theissen J; Westermann F; Brors B; Fischer M
    J Clin Oncol; 2010 Jul; 28(21):3506-15. PubMed ID: 20567016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma.
    Spitz R; Hero B; Simon T; Berthold F
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3368-73. PubMed ID: 16740759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome.
    Oberthuer A; Hero B; Spitz R; Berthold F; Fischer M
    Clin Cancer Res; 2004 Jul; 10(13):4307-13. PubMed ID: 15240516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature.
    De Preter K; Vermeulen J; Brors B; Delattre O; Eggert A; Fischer M; Janoueix-Lerosey I; Lavarino C; Maris JM; Mora J; Nakagawara A; Oberthuer A; Ohira M; Schleiermacher G; Schramm A; Schulte JH; Wang Q; Westermann F; Speleman F; Vandesompele J
    Clin Cancer Res; 2010 Mar; 16(5):1532-41. PubMed ID: 20179214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
    George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
    J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroblastoma in adolescents: the Italian experience.
    Conte M; Parodi S; De Bernardi B; Milanaccio C; Mazzocco K; Angelini P; Viscardi E; Di Cataldo A; Luksch R; Haupt R
    Cancer; 2006 Mar; 106(6):1409-17. PubMed ID: 16475209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
    Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
    J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
    Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
    Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GABAergic system gene expression predicts clinical outcome in patients with neuroblastoma.
    Roberts SS; Mori M; Pattee P; Lapidus J; Mathews R; O'Malley JP; Hsieh YC; Turner MA; Wang Z; Tian Q; Rodland MJ; Reynolds CP; Seeger RC; Nagalla SR
    J Clin Oncol; 2004 Oct; 22(20):4127-34. PubMed ID: 15483022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profiling in uveal melanoma: two regions on 3p related to prognosis.
    van Gils W; Lodder EM; Mensink HW; Kiliç E; Naus NC; Brüggenwirth HT; van Ijcken W; Paridaens D; Luyten GP; de Klein A
    Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4254-62. PubMed ID: 18552379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.